Ozagrel administered in drinking water exacerbated urinary albumin excretion in male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo). In female ICR mice with adenomyosis, Ozagrel was administered intraperitoneally at low or high doses. Compared with untreated mice, both Ozagrel dose groups had significantly less myometrial infiltration. [2,3]
Ozagrel and Urinary Albumin Excretion in Hypertensive Rats
Animal study · male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo) [2]
Male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo) received Ozagrel in drinking water. Ozagrel exacerbated urinary albumin excretion.
Conditions shared by the study groups
- Route
- drinking water
- Treatment course
- provided for 5 weeks
- Vehicle
- water
- Ozagrel 3.5 mmol/L
- Model: male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo)
Methods and source locations
Compound reported in the paper: Ozagrel
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animals (S1); Methods > Experimental protocol > Protocol 2. Pathological roles of TXA2 together with oxidative stress (S12, S13, S22); Results > Pathological roles of TXA2 together with oxidative stress (S70)
urinary albumin excretion (UAE): urinary albumin excretion (UAE); comparator: untreated — Methods > Experimental protocol > Protocol 2. Pathological roles of TXA2 together with oxidative stress (S12, S13, S22); Results > Pathological roles of TXA2 together with oxidative stress (S70)
Ozagrel 3.5 mmol/L · Methods > Experimental protocol > Protocol 2. Pathological roles of TXA2 together with oxidative stress (S12, S13); Results > Pathological roles of TXA2 together with oxidative stress (S70)
Ozagrel and Myometrial Infiltration in Adenomyosis
Animal study · ICR mice; female mice; adenomyosis; Group L, n = 10; Group H, n = 10 [3]
Female ICR mice with adenomyosis received low- or high-dose Ozagrel by intraperitoneal administration. Compared with untreated mice, mice receiving either dose had significantly less myometrial infiltration.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) administration
- Treatment course
- At the 16th week after birth; for 3 weeks, daily
- Vehicle
- 0.9 % normal saline
- Ozagrel 12.5 μg/g; 25 μg/g
- Model: ICR mice; female mice; adenomyosis; Group L, n = 10; Group H, n = 10
- Reported limits: Removed after verification: value.
Methods and source locations
Compound reported in the paper: Ozagrel
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Chemicals (S1); Methods > Animals and the procedure for induction of adenomyosis (S5, S9, S11); Methods > Experimental protocol (S16, S17); Results > Treatment effect on the depth of myometrial infiltration, hotplate latency, and uterine and bodyweight (S83, S84, S87)
depth of myometrial infiltration: depth of myometrial infiltration; comparator: Group U (n = 9), or the untreated group, received the vehicle only — Results > Treatment effect on the depth of myometrial infiltration, hotplate latency, and uterine and bodyweight (S83, S84, S87)
Ozagrel 12.5 μg/g; 25 μg/g · Methods > Experimental protocol (S16, S17); Results > Treatment effect on the depth of myometrial infiltration, hotplate latency, and uterine and bodyweight (S84, S87)